Valneva (NASDAQ:VALN) Trading Up 5% - Here's Why

Key Points

• Valneva's stock price increased by 5% to $9.06, with a trading volume decline of 17% from the average. It had previously closed at $8.63.
• Analysts have mixed sentiments: Guggenheim lowered its price target to $14, while HC Wainwright and Jefferies reaffirmed their "buy" ratings with targets of $18 and $14, respectively.
• The company's recently reported earnings outperformed expectations, with revenue of $54.84 million compared to estimates of $46.28 million, indicating strong financial performance.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shot up 5% on Wednesday . The stock traded as high as $8.99 and last traded at $9.06. 58,840 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 70,963 shares. The stock had previously closed at $8.63.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Guggenheim cut their price objective on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Valneva in a research note on Monday, August 25th. Finally, Jefferies Financial Group set a $14.00 price objective on shares of Valneva and gave the stock a "buy" rating in a report on Monday, August 25th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $15.33.

Valneva Stock Performance

The firm has a market capitalization of $759.43 million, a price-to-earnings ratio of -9.11 and a beta of 1.79. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average price of $7.85 and a 200-day moving average price of $7.05.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The firm had revenue of $54.84 million for the quarter, compared to analyst estimates of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. As a group, analysts anticipate that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

Several institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC acquired a new stake in shares of Valneva in the first quarter valued at approximately $94,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Valneva during the 2nd quarter worth about $8,240,000. Finally, Marex Group plc bought a new position in shares of Valneva in the 2nd quarter valued at about $64,000. Institutional investors own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.